Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Walking during immunotherapy: a new way to fight breast cancer?

NCT ID NCT07216495

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This pilot study tests whether a supervised treadmill walking program can help people with early-stage triple negative breast cancer who are receiving immunotherapy before surgery. The study will enroll 33 participants and measure how well they stick to the exercise plan, as well as changes in immune cells in the blood. The goal is to see if exercise might boost the immune system's response to treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AEROBIC EXERCISE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

supervised aerobic exercise (treadmill walking)

What this could lead to

If it works, this could show that exercise boosts immune cells during immunotherapy, potentially improving treatment outcomes for breast cancer patients.

What could go wrong

This is a very small pilot study with only 33 participants, so results may not apply to everyone. It focuses on feasibility and immune markers, not on curing cancer.

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.